AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)

(2017) J. A. Sosman et al.   JOURNAL OF CLINICAL ONCOLOGY

Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC).

(2017) A. J. Bullock et al.   JOURNAL OF CLINICAL ONCOLOGY

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

(2011) J. Beck et al.   ANNALS OF ONCOLOGY

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

(2011) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

(2011) Beth Y. Karlan et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating biomarkers of bevacizumab activity in patients with breast cancer

(2010) Neelima Denduluri et al.   CANCER BIOLOGY & THERAPY

New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance

(2010) B. I. Rini   CLINICAL CANCER RESEARCH

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

(2010) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer

(2010) Michael B. Bass et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody

(2010) A. Coxon et al.   MOLECULAR CANCER THERAPEUTICS

A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers

(2009) J. Baar et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2009) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

(2009) Thomas E. Hutson et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal cell carcinoma

(2009) Brian I Rini et al.   LANCET

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology